Amendments to the Claims

Listing of Claims

The following Listing of Claims replaces all prior versions and listings of claims in the application.

1. (currently amended) A composition comprising:

(a) a drug in a pharmaceutically acceptable solubility-improved form ~~selected from~~ that is a crystalline highly soluble salt form other than the crystalline hydrochloride salt ~~a high-energy crystalline form, and an amorphous form~~; and

(b) a concentration-enhancing polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methyl cellulose phthalate, and hydroxypropyl methyl cellulose acetate succinate ~~combined with said solubility-improved form in a sufficient amount so that said composition provides, after introduction to a use-environment, a maximum concentration of said drug in said use environment that is at least 1.25-fold an equilibrium concentration of said drug in said use environment, and a concentration of said drug in said use environment that exceeds said equilibrium concentration for a longer time than the concentration of said drug in said use environment provided by a control composition exceeds said equilibrium concentration, wherein said control composition is free from said concentration-enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,~~

wherein

~~said composition is not a dispersion;~~

said drug alone has an aqueous solubility of less than about 1 mg/mL;

when said drug is basic, said solubility-improved form has an aqueous solubility of at least [2] two-fold the solubility of the more soluble of the crystalline hydrochloride salt and the crystalline free base drug form;

~~said concentration-enhancing polymer is a cellulosic ionizable polymer selected from the group consisting of cellulose acetate phthalate, methyl cellulose acetate phthalate, etjyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthatlate succinate, cellulose propionate phthatlate, hydroxypropyl cellulose butyrate phthalate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, cellulose acetate trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate trimellitate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate pyridinedicarboxylate, salicylic acid cellulose acetate, hydroxypropyl sallicylic acidcellulose acetate, ethylbenzoic acid cellulose acetate, hydroxylpropyl ethylbenzoic acidcellulose acetate, ethyl phthalic acide cellulose acetate, ethylnicotinic acid cellulose acetate, carboxymethyl ethyl cellulose and ethyl picolinic acid cellulose acetate~~; and

said composition is not a dispersion and said drug and said polymer are ~~combined~~ present as particles in a ~~simple~~ dry physical mixture ~~wherein both the solubility improved form and the polymer are mixed in particulate form~~.

2. (original) The composition of claim 1 wherein said drug in said solubility-improved form is a crystalline highly soluble salt form of said drug.

3-28 (cancelled)

29. (original) The composition of claim 1 wherein said drug is selected from antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-reducing agents,

antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, and antiviral agents.

30-155 (cancelled)

156. (previously presented) The composition of claim 1, wherein said drug is ziprasidone.

157-163 (cancelled)

164. (currently amended) A composition comprising:

(a) a drug in a crystalline highly soluble salt form other than the crystalline hydrochloride salt; and

(b) hydroxypropyl methyl cellulose acetate succinate

wherein

said composition is not a dispersion;

said drug alone has an aqueous solubility less than about 1 mg/mL;

when said drug is basic, said crystalline highly soluble salt form has an aqueous solubility at least [~~2~~] two-fold the solubility of the crystalline hydrochloride salt form; and

said crystalline highly soluble salt form and said hyroxypropylmethyl cellulose acetate succinate are ~~combined~~ present as particles in a ~~simple~~ dry physical mixture ~~wherein both said crystalline highly soluble salt form and said hydroxypropyl methyl cellulose acetate succinate are mixed in particulate form~~.

165. (new) The composition of claim 1 or 164 wherein said crystalline highly soluble salt form is selected from the group consisting of the bromide, acetate, iodide, mesylate, phosphate, maleate, citrate, sulfate, tartrate, and lactate salts.

166. (new) The composition of claim 1 or 164 wherein said crystalline highly soluble salt form is selected from the group consisting of the sodium, calcium, potassium, zinc, magnesium, lithium, aluminum, meglumine, diethanolamine, benzathine, choline, and procaine salts.

167. (new) The composition of claim 1 or 164 wherein said drug alone has an aqueous solubility of less than about 0.01 mg/mL.

168. (new) The composition of claim 1 or 164 wherein said drug and said polymer are combined without the use of a solvent.